CLINICAL TRIALS PROFILE FOR GLECAPREVIR; PIBRENTASVIR
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Glecaprevir; Pibrentasvir
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02441283 ↗ | A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 | Completed | AbbVie | Phase 2/Phase 3 | 2015-06-22 | This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection. |
| NCT02634008 ↗ | Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P | Recruiting | AbbVie | Phase 3 | 2016-06-01 | An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection. |
| NCT02634008 ↗ | Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P | Recruiting | Kirby Institute | Phase 3 | 2016-06-01 | An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection. |
| NCT02692703 ↗ | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) | Completed | AbbVie | Phase 3 | 2016-04-22 | The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or renal transplant with chronic hepatitis C virus (HCV) infection. |
| NCT02743897 ↗ | Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients | Active, not recruiting | Merck Sharp & Dohme Corp. | Phase 1/Phase 2 | 2016-05-01 | This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation. |
| NCT02743897 ↗ | Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients | Active, not recruiting | University of Pennsylvania | Phase 1/Phase 2 | 2016-05-01 | This study is being conducted to determine safety and effectiveness of transplanting kidneys from Hepatitis C-positive donors into Hepatitis C-negative patients on the kidney transplant waitlist, who will then be treated with the appropriate direct-acting antiviral (DAA) after the single kidney transplantation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Glecaprevir; Pibrentasvir
Condition Name
Clinical Trial Locations for Glecaprevir; Pibrentasvir
Trials by Country
Clinical Trial Progress for Glecaprevir; Pibrentasvir
Clinical Trial Phase
Clinical Trial Sponsors for Glecaprevir; Pibrentasvir
Sponsor Name
